InvestorsHub Logo
Followers 8
Posts 2087
Boards Moderated 0
Alias Born 08/09/2003

Re: DorseyE post# 82

Thursday, 04/16/2020 2:11:33 PM

Thursday, April 16, 2020 2:11:33 PM

Post# of 198
ADHD NDA Filing NDA submission announced March 2, 2020.
Exservan (riluzole) Oral Film Amyotrophic Lateral Sclerosis Approved FDA Approval announced November 22, 2019.
Sympazan Lennox-Gastaut Syndrome Approved Tentative approval issued August 31, 2018. Full approval issued November 2, 2018.
Libervant - AQST-203 Epileptic seizures PDUFA PDUFA date September 27, 2020.
AQST-119 Erectile dysfunction CRL CRL issued November 16, 2018.
APL-130277 Parkinson’s Disease with motor fluctuations PDUFA CRL issued January 30, 2019 through partner Sunovion (private company). NDA refiled. New PDUFA date May 21, 2020.
AQST-108 Anaphylaxis Phase 1 Pivotal pharmacokinetic (PK) trials to be initiated before the end of 2020

Simplified version, click on link...
https://www.biopharmcatalyst.com/company/AQST
Be sure to CLICK ON DRUG INFORMATION
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AQST News